Typical metabolic disorders include, but are not limited to, obesity and diabetes.
AIDP (City of Industry, CA) has gained a U.S. patent for its branded ingredient Magtein magnesium L-threonate in the area of metabolic health. Magtein has been initially promoted as a cognitive-health ingredient.
The patent, No. 8,163,301, is titled “Magnesium compositions and uses thereof for metabolic disorders.” It not only covers Magtein’s unique magnesium compositions but also the use of food, dietary supplements, and drugs containing magnesium L-threonate to combat the effects of metabolic disorder.
Typical metabolic disorders include, but are not limited to, obesity and diabetes. Magtein’s other patents lie in the area of neurological disorders (patent 8,142,803) and food compositions (patent 8,178,132).
Recent animal study finds that Lysoveta may help reduce neonatal brain injury
July 17th 2024A recent animal study found that lysophosphatidylcholine (LPC)-bound omega-3 long-chain polyunsaturated fatty acids (LCPUFAs), marketed as Lysoveta by Aker BioMarine, protected against neonatal hypoxic-ischemic (HI) brain injury in mice.
Meta-analysis does not find increased risk of bleeding events from omega-3 PUFA consumption
July 8th 2024Researchers reviewed 11 studies and found that there was no difference in the incidence of bleeding events between patients receiving omega-3 PUFAs and those not receiving them. High dose EPA consumption was associated with an elevated but modest risk.